MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma

The Journal of Thoracic and Cardiovascular Surgery 2020 May 29 [Link] Tammy Hod, Katherin J Freedberg, Shveta S Motwani, Margaret Chen, Gyorgy Frendl, David E Leaf, Shruti Gupta, Suraj Sarvode Mothi, William G Richards, Raphael Bueno, Sushrut S Waikar Abstract Objectives: Cytoreductive surgery with hyperthermic intraoperative chemotherapy with cisplatin has been used successfully to treat […]

Comments Off on Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma

Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses

Clinical Lung Cancer 2020 May 23 [Link] Juuso Paajanen, Sanna Laaksonen, Ilkka Ilonen, Tapio Vehmas, Mikko I Mäyränpää, Eva Sutinen, Eeva Kettunen, Jarmo A Salo, Jari Räsänen, Henrik Wolff, Marjukka Myllärniemi Abstract Introduction: Malignant pleural mesothelioma (MPM) is a fatal malignancy strongly associated with previous asbestos exposure. Overall survival remains dismal, partly owing to poor […]

Comments Off on Clinical Features in Patients With Malignant Pleural Mesothelioma With 5-Year Survival and Evaluation of Original Diagnoses

Questioning the Prognostic Role of BAP-1 Immunohistochemistry in Malignant Pleural Mesothelioma: A Single Center Experience With Systematic Review and Meta-Analysis

Lung Cancer 2020 June 21 [Link] Luca Cantini, Federica Pecci, Alberto Murrone, Marco Tomasetti, Cecilia Copparoni, Ilaria Fiordoliva, Francesca Morgese, Silvia Rinaldi, Paola Mazzanti, Corrado Rubini, Alessia Cimadamore, Francesca Barbisan, Riccardo Giampieri, Marina Scarpelli, Lory Santarelli, Rossana Berardi Abstract Introduction: The prognostic role of BRCA1 associated protein-1 (BAP1) expression in malignant pleural mesothelioma (MPM) is […]

Comments Off on Questioning the Prognostic Role of BAP-1 Immunohistochemistry in Malignant Pleural Mesothelioma: A Single Center Experience With Systematic Review and Meta-Analysis

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma

Frontiers in Oncology 2020 June 3 [Link] Robert A Belderbos, Heleen Vroman, Joachim G J V Aerts Abstract Malignant pleural mesothelioma (MPM) is a treatment recalcitrant tumor with a poor overall survival (OS). Current approved treatment consists of first line chemotherapy that only modestly increases OS, illustrating the desperate need for other treatment options in […]

Comments Off on Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma

Addition of Radiotherapy to Surgery and Chemotherapy Improves Survival in Localized Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study

Lung Cancer 2020 May 30 [Link] Andrew B Thompson, Thomas J Quinn, Zaid A Siddiqui, Muayad F Almahariq, Inga S Grills, Craig W Stevens Abstract Introduction: Malignant pleural mesothelioma (MPM) is a devastating disease with poor survival outcomes for most patients. Optimizing therapeutic approaches is thus vital, but has been hampered by a dearth of […]

Comments Off on Addition of Radiotherapy to Surgery and Chemotherapy Improves Survival in Localized Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study

Cisplatin Plus Pemetrexed Therapy and Subsequent Immune Checkpoint Inhibitor Administration for Malignant Peritoneal Mesothelioma Without Pleural Lesions: Case Report

Medicine 2020 May 29 [Link] Hiroaki Ikushima, Toshio Sakatani, Sayaka Ohara, Hideyuki Takeshima, Hajime Horiuchi, Teppei Morikawa, Kazuhiro Usui Abstract Rationale: Malignant peritoneal mesothelioma is a rare tumor with a poor prognosis and has no recommended therapy after first-line pemetrexed and platinum-based chemotherapy. Moreover, effects of immune checkpoint inhibitors on peritoneal mesothelioma remains to be […]

Comments Off on Cisplatin Plus Pemetrexed Therapy and Subsequent Immune Checkpoint Inhibitor Administration for Malignant Peritoneal Mesothelioma Without Pleural Lesions: Case Report

Survivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma

Oncology Letters 2020 June [Link] Guozun Zhang, Dong-Liang Yang, Guoqi Zheng, Yufei Liang Abstract Malignant peritoneal mesothelioma (MPeM) is an incurable cancer strongly associated with asbestos exposure and characterised by poor prognosis. The aim of the present study was to elucidate the prognostic and predictive value of CD146 and survivin expression in MPeM. Diagnostic biopsies […]

Comments Off on Survivin Expression as an Independent Predictor of Overall Survival in Malignant Peritoneal Mesothelioma

Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.

Thoracic Cancer 2020 May 4 [Link] Trama A, Proto C, Signorelli D, Garassino MC, Lo Russo G, Ganzinelli M, Prelaj A, Mensi C, Gangemi M, Gennaro V, Chellini E, Caldarella A, Angelillo IF, Ascoli V, Pascucci C, Tagliabue G, Cusimano R, Bella F, Falcini F, Merler E, Masanotti G, Ziino A, Michiara M, Gola G, […]

Comments Off on Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study.

Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.

European Journal of Cancer 2020 April 4 [Link] Torricelli F, Saxena A, Nuamah R, Neat M, Harling L, Ng W, Spicer J, Ciarrocchi A, Bille A Abstract BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive tumour with poor prognosis. The aim of this study was to identify genetic mutations associated with poor or extended survival in […]

Comments Off on Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.

Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.

Clinical Lung Cancer 2020 March 7 [Link] Lau B, Boyer M, Lee JH, Kao S Abstract INTRODUCTION: Studies of bevacizumab and pembrolizumab in the treatment of malignant pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective of real-world patients. We aimed to determine the proportion of real-world patients who would be eligible for […]

Comments Off on Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes.